
    
      Multicentric, Randomized phase III study (1:1), Population: newly diagnosed 1p/19-codeleted
      anaplastic gliomas, Primary objective: To determine whether treating newly diagnosed
      1p/19q-codeleted anaplastic gliomas with PCV alone can increase overall survival without
      neurocognitive deterioration Control group: radiotherapy followed by 6 cycles of PCV
      chemotherapy. Experimental group: 6 cycles of PCV chemotherapy (radiotherapy being deferred
      at the time of progression).

      Number of centres participating: the 31 centers of the POLA network Recruitment duration: 7
      years, the accrual rate being 40 patients per year, and patients are followed-up until the
      end of the trial.
    
  